AVRO AVROBIO Inc.

17.71
+1.29  (+8%)
Previous Close 16.42
Open 17.25
Price To Book 4.01
Market Cap 427,643,813
Shares 24,147,025
Volume 84,823
Short Ratio
Av. Daily Volume 146,590

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial planned for 2H 2019.
AVR-RD-04
Cystinosis
Phase 1/2 trial planned for 2H 2019.
AVR-RD-02
Gaucher disease
Phase 2 preliminary data released July 15, 2019.
AVR-RD-01 (FAB-201)
Fabry disease

Latest News

  1. Why Crocs, Golden Star Resources, and AVROBIO Jumped Today
  2. AVROBIO Announces 87% Substrate Reduction in First Kidney Biopsy and Additional Positive Data from Clinical Trials of AVR-RD-01 Investigational Gene Therapy in Fabry Disease
  3. AVROBIO, Inc. Reports First Quarter 2019 Financial Results and Provides Business Update
  4. Here’s What Hedge Funds Think About AVROBIO, Inc. (AVRO)
  5. AVROBIO, Inc. Announces FDA Clearance of Investigational New Drug Application for AVR-RD-01 Gene Therapy for the Treatment of Fabry Disease
  6. AVROBIO Highlights the plato™ Platform and Gaucher and Cystinosis Programs at the 2019 Annual Meeting of the American Society of Gene and Cell Therapy
  7. AVROBIO, Inc. Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Provides Business Update
  8. AVROBIO, Inc. to Present at the Cowen and Company 39th Annual Health Care Conference
  9. AVROBIO, Inc. Announces Updated Clinical Data from Ongoing Phase 1 and Phase 2 Studies for AVR-RD-01 Gene Therapy for Fabry Disease
  10. Investors Are Undervaluing AVROBIO, Inc. (NASDAQ:AVRO) By 46.82%
  11. AVROBIO, Inc. Announces Time Change for Analyst and Investor Presentation and Webcast, now 5:30 p.m. ET on Wednesday, February 6, 2019
  12. AVROBIO Enters Oversold Territory
  13. AVROBIO, Inc. Announces Acceptance of Investigational New Drug (IND) Application for Investigator-Sponsored Phase 1/2 Clinical Trial for AVR-RD-04 Gene Therapy for Cystinosis
  14. AVROBIO, Inc. Announces Analyst and Investor Event and Upcoming Clinical Data Presentations at WORLDSymposium 2019
  15. AVROBIO, Inc. Appoints Philip J. Vickers to its Board of Directors
  16. AVROBIO, Inc. Added to NASDAQ Biotechnology Index
  17. Should You Avoid AVROBIO, Inc. (AVRO)?
  18. AVROBIO Receives Orphan-Drug Designation from the U.S. FDA for AVR RD 01 for the Treatment of Fabry Disease
  19. AVROBIO, Inc. Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
  20. AVROBIO, Inc. Expands and Strengthens Leadership Team with Four Senior Management Hires